Tag Archives: Iris Zemzoum

Novartis Gains EU Approval for Kisqali® to Broaden Early Breast Cancer Treatment Options

Posted on 27, November 2024 by

(IN BRIEF) Novartis has secured European Commission approval for Kisqali® (ribociclib) in combination with endocrine therapy (ET) as an adjuvant treatment for high-risk hormone receptor-positive (HR+), HER2-negative early breast cancer (EBC). The approval, based on the Phase III NATALEE trial, … Read the full press release →

Posted in Business, European Union, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology

Tagged , , , , , , ,